Stark Reminders Of Why Antibiotic Space Remains Unattractive On Display At FDA Advisory Cmte.
As need for new antibiotics keeps increasing, a recent US FDA advisory panel offers a case study of why industry isn’t keen on the space.
As need for new antibiotics keeps increasing, a recent US FDA advisory panel offers a case study of why industry isn’t keen on the space.